Day One

8:00 am Chair’s Opening Remarks

An Update From the Field – Where Are We Now & What Lies Ahead?

8:10 am An Overview of the 2021 WHO Classification and Implications for Diffuse Glioma Diagnosis

  • David Louis Pathologist-in-Chief, Massachusetts General Hospital


  • Major conceptual changes in the 2021 WHO classification of CNS tumors
  • Major specific changes in the 2021 WHO criteria for diffuse glioma diagnosis

8:40 am Impact of Molecular Classification of GBM on Clinical Trial Design and Analysis

  • Susan Chang Professor Neurological Surgery, UCSF Weill Institute for Neurosciences


  • Review of the molecular classification of GBM
  • Impact on clinical trial design
  • Impact on clinical trial analysis

9:10 am Why Are We Not Doing Better? Overview Of Limitations of Current Drug Development for GBM and Potential Improvements

  • Patrick Wen Director Neuro-Oncology, Dana Farber Cancer Institute


  • Overview of drug development for GBM
  • Discussion of pitfalls and mistakes
  • Potential solutions

9:25 am Panel: Why Are We Not Doing Better? An Open Discussion of the Limitations of Current Drug Development for GBM and Where the Field Can Improve

  • Patrick Wen Director Neuro-Oncology, Dana Farber Cancer Institute
  • Kirk Tanner Chief Scientific Officer, National Brain Tumor Society
  • Shwetal Mehta COO, Ivy Brain Tumor Center


  • Barriers to advancing drug development and strategies to address these
  • Major therapeutic strategies currently under development
  • How can drug developers cut to the real barriers, and debate what is truly required to break through to successful treatments for GBM?

10:00 am Keeping the Passion Going, Harnessing the Passion of a Dynamic Founder


  • Key lessons learned in OurBrainBank’s leadership transition from Founder to CEO
  • The future of patient power – how Jessica Morris’ founding vision for patient engagement is reflected in OBB’s 2022-24 organizational strategy

10:15 am Morning Break & Speed Networking

Cancer Metabolism & The Tumor Micro-Environment

11:15 am Accounting for Cancer on the Spectrum in Drug Development

  • Josh Rubin Neuro-Oncologist, Washington University


  • Appreciate the distinction between sex differences and sexual dimorphism
  • Understanding the utility of Bayesian Nearest Neighbor Analyses in this endeavor
  • Recognize the importance of incorporating sex differences in drug

11:45 am Sex Differences in the GBM Immune Response


  • There are key sex differences in the myeloid compartment in both mouse GBM models and human GBM patients
  • The male tumor microenvironment contains myeloid cells while female
    immune suppression is systemically regulated
  • These sex differences in immune suppression can be leveraged for
    precision medicine based therapeutic strategies

12:15 pm Developmental Pathways, Plasticity and Neural Regulation of Pediatric High-Grade Glioma


  • The architecture of pediatric high-grade gliomas resembles normal
  • Histone 3 mutant gliomas (K27M and G34R/V) have distinct developmental origins
  • Intra-tumoral hierarchy and plasticity is tumor-type specific
  • Targeting lineage specific cancer cell states represents new treatment

12:45 pm Lunch & Networking

Optimizing Clinical Trial Design to Drive Forward Drug Development

1:45 pm Panel: How Nonprofit Foundations Can Synergize With Biopharma to Catalyze New Product Development in GBM

  • Becky Bish Head of Discovery & Preclinical Research, The Mark Foundation

2:30 pm Role of Cytotoxic Agents in GBM

  • Saiid Zarrabian President & Chief Executive Officer, Kintara Therapeutics


  • GBM Treatment Challenges
  • History of VAL-083
  • Unique Mechanism of Action of VAL-083
  • VAL-083 Treatment Arm in the GCAR GBM AGILE Study

3:00 pm Leveraging External Data for the Design and Analysis of Glioblastoma Trials


  • Discuss sources of external data and challenges to data access and data-sharing
  • Design & evaluate the use of real world evidence and clinical trial data to develop external control arms in GBM
  • Assess the utility of external data, including real world data and clinical trial data to increase efficiency of clinical trials in GBM

3:30 pm Paxalisib In Glioblastoma – Key Learnings From A Phase II Study in Newly-Diagnosed Patients


  • Study design and rationale
  • Efficacy and safety outcomes
  • Directions for future research

4:00 pm Afternoon Break & Refreshments

4:30 pm RANO. 2.0 Update in Response Assessment for Glioblastomas

  • Patrick Wen Director Neuro-Oncology, Dana Farber Cancer Institute


  • Outline current limitations of RANO criteria
  • Data comparing RANO, mRANO and iRANO
  • Proposed updates to the RANO criteria

Developing Effective Vaccines for Treatment of GBM

5:00 pm AV-GBM-1 Patient-Specific Vaccines in Newly Diagnosed Primary Glioblastoma


  • AV-GBM-1 product and manufacturing feasibility update
  • Phase 2 safety and survival data including exploratory subset analyses
  • Phase 3 clinical trial considerations and design

5:30 pm Oral DNA Vaccination in Combination With Checkpoint Inhibitor In Recurrent Glioblastoma


  • Cytotoxic T-cell approach targeting VEGFR-2 on tumor vasculature and tumor cells
  • Combination with checkpoint inhibitors
  • Intratumoral immune-biomarkers pre- and post treatment

6:00 pm End of Day One